HDIM
MRNA icon

Hanson & Doremus Investment Management’s Moderna MRNA Stock Holding History

Hanson & Doremus Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9
Closed – – 543
2025
Q4 		$0 Buy
+9
New +$245 ﹤0.01% 507
2022
Q3 		– Sell
-23
Closed -$3K – 531
2022
Q2 		$3K Buy
+23
New +$3.29K ﹤0.01% 510
2022
Q1 		– Sell
-13
Closed -$3K – 526
2021
Q4 		$3K Hold
13
– – ﹤0.01% 470
2021
Q3 		$5K Sell
13
-67
-84% -$24.7K ﹤0.01% 444
2021
Q2 		$6K Buy
80
+67
+515% +$12K ﹤0.01% 386
2021
Q1 		$2K Buy
+13
New +$1.88K ﹤0.01% 481
2020
Q4 		– Sell
-80
Closed -$6K – 439
2020
Q3 		$6K Buy
80
+55
+220% +$3.83K ﹤0.01% 386
2020
Q2 		$2K Buy
+25
New +$1.37K ﹤0.01% 422

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hanson & Doremus Investment Management's MRNA Position: Q1 2026 in Review

Hanson & Doremus Investment Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 9 shares.

Hanson & Doremus Investment Management first reported a position in MRNA in Q2 2020 and held it in 8 quarters. The position peaked at $6K in Q2 2021. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Hanson & Doremus Investment Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 9 Moderna shares in Q1 2026.
  • Hanson & Doremus Investment Management first reported a position in Moderna in Q2 2020 and held it in 8 quarters.
  • Hanson & Doremus Investment Management's Moderna position peaked at $6K in Q2 2021.
  • 726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q1 2026, filed 17 Apr 2026.